Generation and characterization of novel high-affinity fully human antibodies targeting prostate-specific membrane antigen and prostatic acid phosphatase
The lead candidates, termed H92A5 (anti-PSMA) and EKA4 (anti-ACP3), could serve as promising scaffolds for the development of next-generation tumor-targeted therapeutics for prostate cancer.
Authors
- Stefanie K. Pfister (ORCID: https://orcid.org/0000-0002-1394-3716)
- Ettore Gilardoni (ORCID: https://orcid.org/0000-0002-2010-2667)
- Tobias Weiß (ORCID: https://orcid.org/0000-0002-5533-9429)
- Michael Weller (ORCID: https://orcid.org/0000-0002-1748-174X)
- Claudia Comacchio
- Dario Neri (ORCID: https://orcid.org/0000-0001-5234-7370)
- Roberto De Luca (ORCID: https://orcid.org/0000-0001-7519-8689)
- Emanuele Puca (ORCID: https://orcid.org/0000-0002-2869-3203)
- Domenico Ravazza (ORCID: https://orcid.org/0009-0006-5739-8090)
Institutions
- University of Zurich (CH)
- ETH Zurich (CH)
- University Hospital of Zurich (CH)
- Philogen (Italy) (IT)
- Philochem (Switzerland) (CH)
Publication Details
- Journal
- Antibody Therapeutics
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1093/abt/tbaf021
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eidgenössische Technische Hochschule Zürich